LSIEX03:	Listing of Study Treatment Administration for Infusions; Safety Analysis Set (Study jjcs - core)												
Treatment Group 	Subject ID 	Age (years) / Sex / Race 	Visit 	Prescribed Dose Level (unit) 	Dose (unit) 	Total Volume Infused (unit) 	Infusion Rate (unit) 	Start Date / Time (Study Daya) 	End Date / Time (Study Daya) 	Action Taken / Reason Prior to Infusion 	Action Taken / Reason During Infusion 	
Xanomeline High Dose 	01-701-1028 	71 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	19JUL2013 / 03:00 (1) 	01AUG2013 / --:-- (14) 	Dose re-escalated / N/A 	Infusion rate increased / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	02AUG2013 / 10:00 (15) 	06JAN2014 / --:-- (172) 	 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 24 	7.5 mg 	300 mg 	300 mg 	300 mg 	07JAN2014 / 11:00 (173) 	14JAN2014 / --:-- (180) 	Dose re-escalated / N/A 	 	
 	01-701-1034 	77 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	01JUL2014 / 17:00 (1) 	15JUL2014 / --:-- (15) 	Same dose as prior infusion / N/A 	 	
 	 	 	WEEK 2 	0 mg 	60 mg 	60 mg 	60 mg 	16JUL2014 / 10:00 (16) 	17DEC2014 / --:-- (170) 	Study drug permanently discontinued / Adverse event 	Infusion interrupted / Adverse event 	
 	 	 	WEEK 24 	0 mg 	60 mg 	60 mg 	60 mg 	18DEC2014 / 07:00 (171) 	30DEC2014 / --:-- (183) 	Same dose as prior infusion / Adverse event 	 / Adverse event 	
 	01-701-1133 	81 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	28OCT2012 / 08:00 (1) 	12NOV2012 / --:-- (16) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	13NOV2012 / 08:00 (17) 	18APR2013 / --:-- (173) 	Infusion delayed within the cycle / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 24 	7.5 mg 	480 mg 	480 mg 	480 mg 	19APR2013 / 00:00 (174) 	28APR2013 / --:-- (183) 	 	 	
 	01-701-1146 	75 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	20MAY2013 / 17:00 (1) 	03JUN2013 / --:-- (15) 	Study drug permanently discontinued / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	04JUN2013 / 05:00 (16) 	26JUN2013 / --:-- (38) 	Dose re-escalated / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-701-1148 	57 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	23AUG2013 / 01:00 (1) 	05SEP2013 / --:-- (14) 	Dose reduced compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	06SEP2013 / 12:00 (15) 	08FEB2014 / --:-- (170) 	Study drug permanently discontinued / N/A 	Infusion rate increased / N/A 	
 	 	 	WEEK 24 	0 mg 	60 mg 	60 mg 	60 mg 	09FEB2014 / 10:00 (171) 	20FEB2014 / --:-- (182) 	Infusion delayed within the cycle / Other: ************ 	Full dose administered without interruption or rate change / Other: Sheet could not into the bladder 	
 	01-701-1180 	56 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	12FEB2013 / 02:00 (1) 	25FEB2013 / --:-- (14) 	Same dose as prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	26FEB2013 / 04:00 (15) 	18MAR2013 / --:-- (35) 	Study drug permanently discontinued / N/A 	 	
 	01-701-1239 	56 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	11JAN2014 / 05:00 (1) 	25JAN2014 / --:-- (15) 	Same dose as prior infusion / N/A 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	26JAN2014 / 05:00 (16) 	27JUN2014 / --:-- (168) 	Study drug permanently discontinued / N/A 	 	
 	 	 	WEEK 24 	7.5 mg 	480 mg 	480 mg 	480 mg 	28JUN2014 / 15:00 (169) 	10JUL2014 / --:-- (181) 	Infusion rate decreased compared to prior infusion / N/A 	Infusion interrupted / N/A 	
 	01-701-1275 	61 / Male / American Indian or Alaska Native 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	07FEB2014 / 00:00 (1) 	22FEB2014 / --:-- (16) 	Same dose as prior infusion / N/A 	Infusion rate increased / N/A 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	23FEB2014 / 02:00 (17) 	31MAY2014 / --:-- (114) 	Infusion rate decreased compared to prior infusion / N/A 	Infusion aborted / N/A 	
 	01-701-1287 	56 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	25JAN2014 / 22:00 (1) 	11FEB2014 / --:-- (18) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	12FEB2014 / 22:00 (19) 	12JUL2014 / --:-- (169) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	13JUL2014 / 18:00 (170) 	26JUL2014 / --:-- (183) 	Infusion skipped (and not made up) / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-701-1302 	61 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	29AUG2013 / 03:00 (1) 	15SEP2013 / --:-- (18) 	Dose reduced compared to prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	16SEP2013 / 20:00 (19) 	05NOV2013 / --:-- (69) 	Dose re-escalated / N/A 	Infusion interrupted / N/A 	
 	01-701-1383 	72 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	04FEB2013 / 16:00 (1) 	19FEB2013 / --:-- (16) 	 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	20FEB2013 / 01:00 (17) 	30JUL2013 / --:-- (177) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 24 	7.5 mg 	300 mg 	300 mg 	300 mg 	31JUL2013 / 07:00 (178) 	06AUG2013 / --:-- (184) 	Infusion delayed within the cycle / N/A 	 	
 	01-701-1444 	63 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	05JAN2013 / 09:00 (1) 	18JAN2013 / --:-- (14) 	Dose re-escalated / N/A 	Infusion interrupted / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	19JAN2013 / 16:00 (15) 	12FEB2013 / --:-- (39) 	Dose reduced compared to prior infusion / N/A 	 	
 	01-703-1076 	69 / Male / White 	BASELINE 	7.5 mg 	480 mg 	480 mg 	480 mg 	25OCT2013 / 16:00 (1) 	06NOV2013 / --:-- (13) 	Infusion rate decreased compared to prior infusion / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	07NOV2013 / 05:00 (14) 	24DEC2013 / --:-- (61) 	Infusion rate decreased compared to prior infusion / N/A 	Infusion aborted / N/A 	
 	01-703-1258 	78 / Female / White 	BASELINE 	7.5 mg 	480 mg 	480 mg 	480 mg 	20JUL2012 / 05:00 (1) 	01AUG2012 / --:-- (13) 	Infusion delayed within the cycle / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	02AUG2012 / 18:00 (14) 	31DEC2012 / --:-- (165) 	Same dose as prior infusion / N/A 	 	
 	 	 	WEEK 24 	7.5 mg 	480 mg 	480 mg 	480 mg 	01JAN2013 / 17:00 (166) 	11JAN2013 / --:-- (176) 	Same dose as prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-703-1295 	88 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	21NOV2013 / 13:00 (1) 	05DEC2013 / --:-- (15) 	Study drug permanently discontinued / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	06DEC2013 / 05:00 (16) 	19APR2014 / --:-- (150) 	Dose reduced compared to prior infusion / N/A 	Infusion rate increased / N/A 	
 	01-703-1335 	67 / Female / Black or African American 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	17MAR2014 / 10:00 (1) 	31MAR2014 / --:-- (15) 	 	Infusion rate increased / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	01APR2014 / 16:00 (16) 	07MAY2014 / --:-- (52) 	Dose reduced compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-703-1439 	76 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	12MAR2014 / 11:00 (1) 	26MAR2014 / --:-- (15) 	Infusion skipped (and not made up) / N/A 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	27MAR2014 / 12:00 (16) 	28AUG2014 / --:-- (170) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	29AUG2014 / 17:00 (171) 	11SEP2014 / --:-- (184) 	Study drug permanently discontinued / N/A 	Infusion aborted / N/A 	
 	01-704-1008 	76 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	13JAN2013 / 16:00 (1) 	28JAN2013 / --:-- (16) 	Infusion skipped (and not made up) / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	29JAN2013 / 00:00 (17) 	21FEB2013 / --:-- (40) 	 	Infusion aborted / N/A 	
 	01-704-1017 	77 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	06OCT2013 / 00:00 (1) 	19OCT2013 / --:-- (14) 	Dose re-escalated / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	20OCT2013 / 17:00 (15) 	18NOV2013 / --:-- (44) 	Dose re-escalated / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-704-1065 	75 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	24OCT2013 / 21:00 (1) 	07NOV2013 / --:-- (15) 	 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	08NOV2013 / 01:00 (16) 	22DEC2013 / --:-- (60) 	Study drug permanently discontinued / N/A 	 	
 	01-704-1074 	80 / Female / White 	BASELINE 	7.5 mg 	960 mg 	960 mg 	960 mg 	22JAN2014 / 20:00 (1) 	09FEB2014 / --:-- (19) 	Dose re-escalated / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	10FEB2014 / 09:00 (20) 	20MAR2014 / --:-- (58) 	 	Infusion rate increased / N/A 	
 	01-704-1093 	79 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	15MAR2013 / 10:00 (1) 	30MAR2013 / --:-- (16) 	Same dose as prior infusion / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	31MAR2013 / 07:00 (17) 	17JUN2013 / --:-- (95) 	 	Infusion interrupted / N/A 	
 	01-704-1241 	86 / Male / White 	BASELINE 	7.5 mg 	480 mg 	480 mg 	480 mg 	25AUG2013 / 19:00 (1) 	05SEP2013 / --:-- (12) 	Infusion rate decreased compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	06SEP2013 / 08:00 (13) 	09OCT2013 / --:-- (46) 	Dose re-escalated / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-704-1266 	82 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	13OCT2013 / 20:00 (1) 	27OCT2013 / --:-- (15) 	Infusion skipped (and not made up) / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	28OCT2013 / 11:00 (16) 	06DEC2013 / --:-- (55) 	Dose re-escalated / N/A 	 	
 	01-704-1332 	80 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	09DEC2013 / 11:00 (1) 	23DEC2013 / --:-- (15) 	 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	24DEC2013 / 06:00 (16) 	14FEB2014 / --:-- (68) 	Study drug permanently discontinued / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-705-1280 	56 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	17JAN2014 / 01:00 (1) 	31JAN2014 / --:-- (15) 	 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	01FEB2014 / 22:00 (16) 	11JUL2014 / --:-- (176) 	Dose reduced compared to prior infusion / N/A 	Infusion interrupted / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	12JUL2014 / 01:00 (177) 	25JUL2014 / --:-- (190) 	Dose re-escalated / N/A 	 	
 	01-705-1281 	73 / Female / Black or African American 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	28NOV2013 / 00:00 (1) 	15DEC2013 / --:-- (18) 	Infusion skipped (and not made up) / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	16DEC2013 / 07:00 (19) 	27FEB2014 / --:-- (92) 	Infusion rate decreased compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-705-1303 	72 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	16DEC2013 / 12:00 (1) 	30DEC2013 / --:-- (15) 	 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	 	 	 	31DEC2013 / 22:00 (16) 	 	 	Full dose administered without interruption or rate change / N/A 	
 	01-705-1310 	74 / Female / White 	BASELINE 	7.5 mg 	960 mg 	960 mg 	960 mg 	02NOV2013 / 13:00 (1) 	22NOV2013 / --:-- (21) 	Same dose as prior infusion / N/A 	Infusion interrupted / N/A 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	23NOV2013 / 23:00 (22) 	23JAN2014 / --:-- (83) 	Dose re-escalated / N/A 	Infusion rate increased / N/A 	
 	01-705-1377 	63 / Female / Black or African American 	BASELINE 	7.5 mg 	960 mg 	960 mg 	960 mg 	04JAN2014 / 08:00 (1) 	25JAN2014 / --:-- (22) 	Dose reduced compared to prior infusion / N/A 	Infusion interrupted / N/A 	
 	 	 	WEEK 2 	15 mg 	 	 	 	26JAN2014 / 21:00 (23) 	 	Infusion delayed within the cycle / N/A 	Infusion interrupted / N/A 	
 	01-706-1049 	60 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	14MAY2013 / 01:00 (1) 	28MAY2013 / --:-- (15) 	Dose re-escalated / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	29MAY2013 / 01:00 (16) 	18JUN2013 / --:-- (36) 	Study drug permanently discontinued / N/A 	 	
 	01-708-1178 	77 / Female / Black or African American 	BASELINE 	7.5 mg 	960 mg 	960 mg 	960 mg 	29DEC2013 / 16:00 (1) 	18JAN2014 / --:-- (21) 	 	 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	19JAN2014 / 23:00 (22) 	06APR2014 / --:-- (99) 	Infusion skipped (and not made up) / N/A 	Infusion interrupted / N/A 	
 	01-708-1216 	78 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	24OCT2012 / 08:00 (1) 	08NOV2012 / --:-- (16) 	Dose reduced compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	09NOV2012 / 05:00 (17) 	29NOV2012 / --:-- (37) 	Infusion delayed within the cycle / N/A 	 	
 	01-708-1336 	73 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	07DEC2012 / 03:00 (1) 	21DEC2012 / --:-- (15) 	Infusion delayed within the cycle / N/A 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	22DEC2012 / 09:00 (16) 	22MAY2013 / --:-- (167) 	Dose re-escalated / N/A 	 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	23MAY2013 / 18:00 (168) 	05JUN2013 / --:-- (181) 	 	Full dose administered without interruption or rate change / N/A 	
 	01-708-1347 	61 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	20APR2013 / 07:00 (1) 	04MAY2013 / --:-- (15) 	Dose reduced compared to prior infusion / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	05MAY2013 / 19:00 (16) 	18JUN2013 / --:-- (60) 	Same dose as prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-708-1406 	71 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	26DEC2013 / 15:00 (1) 	09JAN2014 / --:-- (15) 	Infusion delayed within the cycle / N/A 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	10JAN2014 / 12:00 (16) 	16JUN2014 / --:-- (173) 	Infusion rate decreased compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	17JUN2014 / 11:00 (174) 	02JUL2014 / --:-- (189) 	Dose re-escalated / N/A 	 	
 	01-709-1029 	82 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	25DEC2012 / 05:00 (1) 	09JAN2013 / --:-- (16) 	 	Infusion aborted / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	10JAN2013 / 04:00 (17) 	12JUN2013 / --:-- (170) 	Dose reduced compared to prior infusion / N/A 	 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	13JUN2013 / 01:00 (171) 	26JUN2013 / --:-- (184) 	Infusion delayed within the cycle / N/A 	 	
 	01-709-1099 	79 / Female / White 	BASELINE 	7.5 mg 	960 mg 	960 mg 	960 mg 	25OCT2013 / 03:00 (1) 	12NOV2013 / --:-- (19) 	Infusion rate decreased compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	13NOV2013 / 03:00 (20) 	11APR2014 / --:-- (169) 	Infusion rate decreased compared to prior infusion / N/A 	Infusion rate increased / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	12APR2014 / 09:00 (170) 	25APR2014 / --:-- (183) 	Study drug permanently discontinued / N/A 	 	
 	01-709-1168 	72 / Female / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	02AUG2013 / 13:00 (1) 	17AUG2013 / --:-- (16) 	Study drug permanently discontinued / N/A 	 	
 	 	 	WEEK 2 	15 mg 	960 mg 	960 mg 	960 mg 	18AUG2013 / 03:00 (17) 	26SEP2013 / --:-- (56) 	Dose reduced compared to prior infusion / N/A 	Full dose administered without interruption or rate change / N/A 	
 	01-709-1238 	69 / Male / White 	BASELINE 	7.5 mg 	720 mg 	720 mg 	720 mg 	15MAY2013 / 05:00 (1) 	29MAY2013 / --:-- (15) 	Infusion delayed within the cycle / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	1800 mg 	1800 mg 	1800 mg 	30MAY2013 / 16:00 (16) 	06AUG2013 / --:-- (84) 	Dose re-escalated / N/A 	Infusion aborted / N/A 	
 	01-709-1309 	65 / Male / White 	BASELINE 	7.5 mg 	480 mg 	480 mg 	480 mg 	19JUN2013 / 13:00 (1) 	01JUL2013 / --:-- (13) 	Study drug permanently discontinued / N/A 	 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	02JUL2013 / 19:00 (14) 	05DEC2013 / --:-- (170) 	 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 24 	7.5 mg 	720 mg 	720 mg 	720 mg 	06DEC2013 / 16:00 (171) 	19DEC2013 / --:-- (184) 	Dose re-escalated / N/A 	Infusion rate increased / N/A 	
 	01-710-1006 	77 / Male / White 	BASELINE 	7.5 mg 	480 mg 	480 mg 	480 mg 	10FEB2013 / 07:00 (1) 	22FEB2013 / --:-- (13) 	Dose re-escalated / N/A 	Full dose administered without interruption or rate change / N/A 	
 	 	 	WEEK 2 	15 mg 	3600 mg 	3600 mg 	3600 mg 	23FEB2013 / 02:00 (14) 	27JUL2013 / --:-- (168) 	Study drug permanently discontinued / N/A 	 	
 	 	 	WEEK 24 	7.5 mg 	480 mg 	480 mg 	480 mg 	28JUL2013 / 05:00 (169) 	09AUG2013 / --:-- (181) 	Infusion delayed within the cycle / N/A 	 	

a Study day is relative to [the start of [study treatment]]. 	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].	
a Study day is relative to [the start of [study treatment]].